Inactive Instrument

Analyst Reco. Epizyme, Inc.

Equities

EPZM

US29428V1044

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cowen Downgrades Epizyme to Market Perform From Outperform; Price Target is $1.50	28/22/28	MT
Wedbush Cuts Epizyme to Neutral From Outperform, Price Target to $1.45 From $7, Citing Ipsen Offer	27/22/27	MT
HC Wainwright Adjusts Epizyme's Price Target to $6 From $8, Reiterates Buy Rating	03/22/03	MT
HC Wainwright Adjusts Epizyme Price Target to $8 From $10, Maintains Buy Rating	12/22/12	MT
Wedbush Adjusts Price Target for Epizyme to $7 From $9, Maintains Outperform Rating	11/22/11	MT
HC Wainwright Adjusts Epizyme's Price Target to $10 from $15, Keeps Buy Rating	02/22/02	MT
Wedbush Trims Price Target for Epizyme to $9 From $12, Maintains Outperform Rating	02/22/02	MT
EPIZYME : Morgan Stanley Lowers Epizyme to Underweight From Equal-Weight, Price Target to $5 From $10	10/21/10	MT
EPIZYME : HC Wainwright Adjusts Epizyme's Price Target to $15 From $36, Maintains Buy Rating	10/21/10	MT
EPIZYME : Wedbush Cuts Epizyme's Price Target to $12 From $26, Citing 'Lower-Than-Expected' Tazverik Sales; Outperform Rating Kept	10/21/10	MT
EPIZYME : Morgan Stanley Adjusts Epizyme's Price Target to $10 From $11, Keeps Equal-Weight Rating	07/21/07	MT
EPIZYME : SVB Leerink Upgrades Epizyme to Outperform From Market Perform, Adjusts Price Target to $16 From $12	07/21/07	MT
EPIZYME : Wedbush Adjusts Epizyme's Price Target to $26 From $27, Maintains Outperform Rating	07/21/07	MT
EPIZYME : Morgan Stanley Adjusts Price Target on Epizyme to $11 From $14, Maintains Equal-Weight Rating	19/21/19	MT
EPIZYME : Credit Suisse Starts Epizyme at Outperform with $13 Price Target	31/21/31	MT
EPIZYME : Morgan Stanley Downgrades Epizyme to Equal-Weight From Overweight; Price Target is $14	25/21/25	MT
EPIZYME : Jefferies Downgrades Epizyme to Hold From Buy, Adjusts Price Target to $14 From $18	21/20/21	MT
EPIZYME : Barclays Adjusts Epizyme's Price Target to $18 From $33, Maintains Overweight Rating	09/20/09	MT
EPIZYME : Morgan Stanley Adjusts Epizyme PT to $27 From $29, Maintains Overweight Rating	09/20/09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer